Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12610000623099
Ethics application status
Approved
Date submitted
22/07/2010
Date registered
29/07/2010
Date last updated
27/05/2015
Type of registration
Prospectively registered
Titles & IDs
Public title
Distal Ureteric Stones and Tamsulosin - the D.U.S.T. trial
Query!
Scientific title
Tamsulosin for the treatment of Distal Ureteric Calculi: A Double-Blinded, Placebo-Controlled, Randomised, Multi-Centre Trial (The DUST Trial)
Query!
Secondary ID [1]
252270
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1116-1717
Query!
Trial acronym
The D.U.S.T. Trial
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Distal Ureteric calculi
257791
0
Query!
Condition category
Condition code
Renal and Urogenital
257963
257963
0
0
Query!
Other renal and urogenital disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The intervention group will recieve Tamsulosin 0.4mg orally, daily for 28 days (Standard care will include analgesia with Indomethicin 25-50mg orally three times a day or 100mg suppository twice a day AND Oxycodone 5-10mg orally three times a day as needed)
Query!
Intervention code [1]
256857
0
Treatment: Drugs
Query!
Comparator / control treatment
The control group will recieve Placebo, one tablet orally, daily for 28 days. (Standard care will include analgesia with Indomethicin 25-50mg orally three times a day or 100mg suppository twice a day AND Oxycodone 5-10mg orally three times a day as needed)
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
258830
0
Stone expulsion (assessed by repeat Computed Tomography)
Query!
Assessment method [1]
258830
0
Query!
Timepoint [1]
258830
0
28 days after enrolment
Query!
Primary outcome [2]
258831
0
Time to stone expulsion (as reported by participants)
Query!
Assessment method [2]
258831
0
Query!
Timepoint [2]
258831
0
Up to 28 days (participants will be asked to maintain a diary, and contacted by phone weekly for a structured interview, and in person at 28 days after enrolment)
Query!
Secondary outcome [1]
264936
0
Un-planned representation to the Emergency Department and/or Hospital admission (as reported by patients at structured interviews and cross checked with participating hospital databases).
Query!
Assessment method [1]
264936
0
Query!
Timepoint [1]
264936
0
28 days from enrolment
Query!
Secondary outcome [2]
264937
0
Analgesia requirements (total doses of Indomethicin and Oxycodone) - as recorded in paticipant diaries and reported by participants at structured interviews
Query!
Assessment method [2]
264937
0
Query!
Timepoint [2]
264937
0
28 days from enrolment
Query!
Secondary outcome [3]
264938
0
Pain scores (measured on a verbal numeric pain scale recorded in patient diaries highest per 24 hr period) as recorded in paticipant diaries and reported by participants at structured interviews
Query!
Assessment method [3]
264938
0
Query!
Timepoint [3]
264938
0
28 days from enrolment
Query!
Secondary outcome [4]
264939
0
Urological interventions required for any reason (as reported by patients at structured interviews and cross checked with participating hospital databases)
Query!
Assessment method [4]
264939
0
Query!
Timepoint [4]
264939
0
28 days from enrolment
Query!
Secondary outcome [5]
264940
0
Rates of complications (i.e. Infection by positive culture of pathogenic bacteria in blood or urine, and renal impairment as defined by decrease in Glomerular Filtration Rate of > 20 ml/min/1.73m2)
Query!
Assessment method [5]
264940
0
Query!
Timepoint [5]
264940
0
28 days from enrolment
Query!
Secondary outcome [6]
264941
0
Days off work (recorded in patient diary)
Query!
Assessment method [6]
264941
0
Query!
Timepoint [6]
264941
0
28 days from enrolment
Query!
Secondary outcome [7]
264942
0
Reported adverse effects from study drugs (monitored weekly in structured interview e.g. dizziness, palpitations, tachycardia, hypotension, orthostatic hypotension, syncope, depressed level of consciousness, abnormal ejaculation, headache, asthenia, fatigue, somnolence, rhinitis and nasal congestion)
Query!
Assessment method [7]
264942
0
Query!
Timepoint [7]
264942
0
28 days from enrolment
Query!
Eligibility
Key inclusion criteria
Radiologically documented calculus in the distal ureter, less than or equal to 10mm diameter and no exclusion criteria.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Paediatric Patients <18 years, Infection (fever > 38 degrees), Glomerular Filtration Rate < 60 ml/min/1.73m2, Calculus >1cm diameter, Solitary kidney, Transplanted kidney, History of ureteral stricture, Pregnancy or planning pregnancy, Allergic reaction to the study medication, Current calcium channel blocker or a1-blocker use, Hypotension (Systolic Blood Pressure < 100 mmHg)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computerised sequence generation
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Stratified by stone size (0-5mm and >5mm)
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
20/08/2010
Query!
Actual
29/08/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
7/03/2015
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
500
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
3848
0
The Townsville Hospital - Douglas
Query!
Recruitment hospital [2]
3849
0
Gold Coast Hospital - Southport
Query!
Recruitment hospital [3]
3850
0
Royal Brisbane & Womens Hospital - Herston
Query!
Recruitment hospital [4]
3851
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment postcode(s) [1]
9733
0
4814 - Aitkenvale
Query!
Funding & Sponsors
Funding source category [1]
257315
0
Charities/Societies/Foundations
Query!
Name [1]
257315
0
Queensland Emergency Medicine Research Foundation (QEMRF)
Query!
Address [1]
257315
0
Queensland Emergency Medicine Research Foundation
c/o Australian Medical Association Queensland,
88 L?Estrange Tce, Red Hill, Queensland 4059
PO Box 123, Red Hill, QLD 4059
Query!
Country [1]
257315
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
The Townsville Hospital
Query!
Address
100 Angus Smith Drive
Douglas, Townsville QLD
4814
Query!
Country
Australia
Query!
Secondary sponsor category [1]
256560
0
None
Query!
Name [1]
256560
0
Query!
Address [1]
256560
0
Query!
Country [1]
256560
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
259344
0
Townsville health service district - Human Research Ethics Committee
Query!
Ethics committee address [1]
259344
0
100 Angus Smith Dirve Douglas, Townsville 4814 Queensland
Query!
Ethics committee country [1]
259344
0
Australia
Query!
Date submitted for ethics approval [1]
259344
0
Query!
Approval date [1]
259344
0
17/11/2009
Query!
Ethics approval number [1]
259344
0
HREC/09/QTHS/105
Query!
Ethics committee name [2]
259345
0
Royal Brisbane and Womens Hospital - Metro north Health Service District Human Research Ethics Committee
Query!
Ethics committee address [2]
259345
0
Butterfield St, Herston QLD 4029
Query!
Ethics committee country [2]
259345
0
Australia
Query!
Date submitted for ethics approval [2]
259345
0
Query!
Approval date [2]
259345
0
24/03/2010
Query!
Ethics approval number [2]
259345
0
HREC/10/QRBW/105
Query!
Summary
Brief summary
Ureteric colic (or Kidney stones) is a significant public health concern within Australia, affecting as many as 5-15% of adults. As a result, a significant number of Australians experience significant pain, hospital and outpatient visits, and the potential for more significant complications such as infection, kidney damage and the need for surgical treatments. Although several methods of medical treatments to improve care of such patients have been studied overseas, some of which appear promising, the practice of “medical expulsive therapy” for ureteric colic is not widely practiced in Australia. One such medication is Tamsulosin, which seems to have an effect on the ureter (tube from kidney to bladder) and helps stones pass. It is already in use for other urological conditions already in Australia, and studies overseas seem to show benefit for patients with Ureteric colic. Within Queensland Health there is substantial variation with regard to access to specialist urologist services. Benefits of medical therapies for ureteric colic may be even greater in geographically isolated areas without full time urology services. This study aims to determine if the addition of the drug Tamsulosin 0.4mg daily, in addition to usual standard care, will improve the rates of spontaneously passing stones less than 10mm in diameter, whether the drug has any effect on pain experienced by the patients, their need for surgery and complications. Patients who present to the participating emergency departments with Ureteric calculi, that fit the inclusion criteria will be randomly allocated to either the study medication (Tamsulosin 0.4mg daily) or placebo. The patients will then be closely monitored for four weeks, to determine if the stones pass spontaneously, or if any complications occur. At four weeks the study will be complete, patients who are yet to have passed the stone, would be referred to Urology for consideration of a procedure.
Query!
Trial website
Query!
Trial related presentations / publications
Pending
Query!
Public notes
Query!
Contacts
Principal investigator
Name
31421
0
A/Prof Jeremy Furyk
Query!
Address
31421
0
c/o the Townsville Hospital
Angus Smith Drive
Douglas Qld 4814
Query!
Country
31421
0
Australia
Query!
Phone
31421
0
+61 7 4433 1111
Query!
Fax
31421
0
Query!
Email
31421
0
[email protected]
Query!
Contact person for public queries
Name
14668
0
Jeremy Furyk
Query!
Address
14668
0
c/o The Townsville Hospital
Emergency Department
100 Angus Smith Drive
Douglas QLD 4814
Query!
Country
14668
0
Australia
Query!
Phone
14668
0
+61 7 4796 1111
Query!
Fax
14668
0
+61 7 4796 2901
Query!
Email
14668
0
[email protected]
Query!
Contact person for scientific queries
Name
5596
0
Jeremy Furyk
Query!
Address
5596
0
c/o The Townsville Hospital
Emergency Department
100 Angus Smith Drive
Douglas QLD 4814
Query!
Country
5596
0
Australia
Query!
Phone
5596
0
+61 7 4796 1111
Query!
Fax
5596
0
+61 7 4796 2901
Query!
Email
5596
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF